$BEAM

Tech M&A deals: Wandercraft, Ekso Bionics, Automation Anywhere, Boost.ai, Beam Global, ScoutDI, Altaris

Wandercraft acquired Ekso Bionics to form a global medical exoskeleton company. Automation Anywhere agreed to buy Boost.ai for conversational AI. Beam Global will acquire ScoutDI for $24M to expand drone tech. Altaris completed a $600M deal for Clarivate's healthcare business.

Original reporting
Published Oct 8, 2026, 4:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 10:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tech M&A deals: Wandercraft, Ekso Bionics, Automation Anywhere, Boost.ai, Beam Global, ScoutDI, Altaris — source image
Decision brief

The 30-second read

$BEAMBullishMed
01

Why it matters

Each deal introduces strategic capabilities for the acquirers and may trigger stock moves as investors price in synergies and risks.

02

Market read

These announcements represent fresh, material M&A activity in the tech sector, offering immediate trading catalysts for the involved public companies.

03

What to watch

Regulatory approvals and potential cultural integration challenges for cross‑border deals.

Relevance 7/10Novelty 7/10Timing: immediate announcement

Background

The article lists several newly announced technology M&A transactions across robotics, AI, and life‑sciences.

Company-level read

Ticker impact

$BEAMBullishHigh confidence
Context

Beam Global signed a definitive agreement to acquire ScoutDI for approximately $24 million.

Expected impact

likely upside as the market prices in growth potential from the drone acquisition

Evidence & confidence

The acquisition is a fresh, material deal with cash and stock components, providing clear catalyst.

$CLVTNeutralHigh confidence
Context

Altaris completed a $600 million acquisition of Clarivate’s Life Sciences & Healthcare business.

Expected impact

possible short‑term pressure as the business is divested and earnings adjust

Evidence & confidence

The transaction is newly disclosed, sizable, and will affect Clarivate’s revenue mix.

Market effects

Consolidation in medical exoskeletons and AI‑driven drone markets may spur further M&A activity.

European and US robotics sectors could see valuation adjustments.

These deals highlight growing investment in automation and healthcare robotics worldwide.

Counterpoint

Acquisition premiums may be overvalued; integration risk could depress post‑deal performance.

Key entities

  • Wandercraft

    French‑American robotics firm acquiring Ekso Bionics.

  • Automation Anywhere

    Automation software provider acquiring Boost.ai.

  • Beam Global

    Drone and energy solutions company acquiring ScoutDI.

  • Altaris

    Healthcare investment firm completing acquisition of Clarivate’s life‑sciences unit.

Related articles

$CLVTMed

Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation

Clarivate (NYSE: CLVT) completed the $600M sale of its Life Sciences & Healthcare segment to Altaris, simplifying its portfolio and focusing on Academia & Government and Intellectual Property segments. The company plans to use proceeds to reduce debt and strengthen its balance sheet, aiming to drive growth and shareholder value. Clarivate will update its full-year 2026 guidance on November 3, 2026.